claim
enzym
heat
shock
protein
relat
cxc
chemokin
connectivetissueactiv
peptid
iii
ctap
studi
distinguish
secret
intracellular
enzym
suggest
may
famili
heparanas
protein
differ
substrat
specif
potenti
function
studi
perform
bame
et
al
focus
intracellular
heparanas
involv
normal
catabol
hs
claim
insid
cell
enzym
import
normal
catabol
hs
proteoglycan
hspg
gener
glycosaminoglycan
fragment
transport
lysosom
complet
degrad
character
short
glycosaminoglycan
produc
chines
hamster
ovari
cho
cell
suggest
multipl
heparanas
necessari
format
short
hs
chain
base
abil
bind
ionexchang
resin
elut
gelfiltr
column
four
separ
heparanas
activ
partial
purifi
four
activ
cleav
free
glycosaminoglycan
broad
ph
rang
suggest
act
endosomallysosom
pathway
suggest
format
short
hspg
insid
cho
cell
may
result
concert
action
multipl
heparanas
may
depend
proport
differ
enzym
environ
chain
degrad
larg
part
lay
summari
present
taken
commentari
written
dr
eccl
finkel
respons
heparanas
clone
paper
publish
vlodavski
et
al
hulett
et
al
commentari
found
suitabl
current
histor
review
virtu
accuraci
high
relev
heparanas
research
perform
sinc
tumor
cell
invas
secondari
spread
blood
lymphat
hallmark
malign
diseas
greatest
impedi
cancer
cure
two
essenti
process
requir
metastasi
neoangiogenesi
tumor
cell
invas
basement
membran
bm
extracellular
matrix
ecm
prior
clone
heparanas
gene
attent
focus
serin
cystein
proteas
matrix
metalloproteinas
mmp
although
metastas
cancer
cell
may
produc
mani
differ
matrixdigest
metalloproteinas
clone
heparanas
gene
differ
group
indic
one
heparanas
activ
inhibit
heparanas
nt
around
cover
addit
structur
protein
ie
collagen
laminin
fibronectin
vitronectin
cleav
mmp
bm
ecm
chief
compon
glycosaminoglycan
mainli
heparan
sulfat
proteoglycan
hspg
hspg
compos
protein
core
coval
link
hs
glycosaminoglycan
chain
interact
close
ecm
compon
endoglycosidas
activ
heparanas
degrad
hs
side
chain
hspg
normal
found
mainli
platelet
placent
trophoblast
leukocyt
given
abund
tumor
tissu
appear
normal
physiolog
function
proteas
heparanas
embryon
morphogenesi
wound
heal
tissu
repair
inflamm
effect
hijack
tumor
cell
evid
indic
heparanas
assist
breakdown
ecm
bm
also
involv
regul
bioavail
growth
factor
cytokin
exampl
basic
fibroblast
growth
factor
bfgf
heparinbind
growth
factor
ie
hbegf
vegf
hgf
sequest
hs
provid
local
readili
access
depot
protect
proteolyt
degrad
yet
avail
activ
cell
promot
angiogenesi
releas
heparanas
suggest
releas
tissuespecif
growth
factor
may
involv
organ
select
metastasi
format
metastat
nich
although
phenomena
welldocu
taken
year
purifi
heparanas
protein
clone
respect
gene
mainli
instabl
enzym
low
abund
normal
cell
tissu
lack
robust
accur
rapid
assay
enzym
activ
research
first
made
connect
metastasi
heparanas
three
group
garth
nicolson
anderson
cancer
center
houston
christoph
parish
john
curtin
school
medic
research
canberra
israel
vlodavski
hadassahhebrew
univers
jerusalem
follow
find
natur
anticoagul
heparin
inhibit
spread
cancer
anim
prevail
belief
heparin
work
prevent
platelet
clot
around
cancer
cell
event
like
help
cell
lodg
ultim
penetr
vessel
wall
heparin
famili
molecul
inhibit
clot
format
three
group
independ
show
still
inhibit
metastasi
even
deplet
anticlot
activ
year
later
demonstr
heparin
inhibit
heparanas
enzymat
activ
competit
hs
bind
heparinh
bind
domain
hbd
heparanas
parish
vlodavski
report
heparanas
help
immun
cell
travers
blood
vessel
wall
way
infect
site
evid
might
someth
similar
cancer
cell
immedi
made
research
think
get
better
heparanas
inhibitor
get
pure
enzym
prove
difficult
heparanas
unstabl
assay
avail
slow
cumbersom
nevertheless
isra
group
final
manag
purifi
heparanas
human
liver
cancer
cell
line
also
human
placenta
australian
group
purifi
human
platelet
parallel
toyoshima
nakajima
report
purif
human
heparanas
embryon
fibroblast
cell
line
kussi
et
al
isol
purifi
enzym
human
hepatoma
cell
determin
peptid
amino
acid
sequenc
deriv
purifi
protein
research
screen
est
databas
look
gene
sequenc
could
encod
amino
acid
sequenc
contrari
expect
might
one
heparanas
four
group
found
gene
one
like
databas
soon
genom
organ
chromosom
local
newli
identifi
human
heparanas
gene
report
clone
express
purif
mous
heparanas
ident
human
enzym
report
miao
et
al
recombin
mous
heparanas
protein
purifi
homogen
cell
lysat
combin
cona
affin
chromatographi
heparin
affin
chromatographi
size
exclus
chromatographi
purif
step
commonli
use
nowaday
experi
confirm
newli
clone
gene
aid
spread
cancer
cell
vlodavski
colleagu
introduc
heparanas
gene
nonmetastat
mous
melanoma
lymphoma
cancer
cell
turn
rampantli
malign
cell
colon
lung
liver
inject
mice
parish
look
sever
differ
type
rat
cancer
cell
found
invas
correl
activ
heparanas
gene
convers
inhibit
enzym
inhibit
cancer
metastasi
parish
report
previous
identifi
inhibitor
heparanas
call
decreas
number
lung
tumor
form
breast
cancer
cell
inject
rat
also
cut
blood
suppli
primari
tumor
slow
tumor
growth
encourag
anim
result
led
progen
brisban
australia
test
safeti
inhibitor
healthi
volunt
follow
clinic
trial
cancer
patient
notabl
studi
aim
determin
role
heparanas
tumor
progress
reli
use
heparinmimick
molecul
inhibit
heparanas
activ
reagent
use
studi
lack
specif
conclus
somewhat
debat
inconclus
took
anoth
year
gener
heparanas
neutral
monoclon
antibodi
mab
demonstr
abil
inhibit
lymphoma
tumor
growth
dissemin
notabl
inhibitori
activ
mab
lower
heparin
mimet
ie
rais
issu
drug
specif
vs
effici
nowaday
heparanas
well
establish
cancer
drug
target
sever
inhibitor
progress
clinic
trial
recent
year
heparanas
also
implic
rang
diseas
diabet
complic
kidney
diseas
atherosclerosi
viral
infect
name
continu
fuel
research
protein
studi
perform
clone
heparanas
gene
contribut
immens
understand
key
featur
biolog
enzym
mode
action
involv
cancer
metastasi
inflamm
abstract
select
histor
studi
refer
introduct
present
chronolog
order
purpos
select
abstract
provid
histor
perspect
heparanas
research
develop
progress
time
rather
highlight
promin
influenti
paper
chondroitin
sulfat
dermatan
sulfat
hyaluron
acid
heparan
sulfat
commerci
heparin
ph
optimum
degrad
macromolecular
heparin
around
ph
analysi
degrad
product
show
major
radioact
compon
behav
like
lgulon
acid
sinc
h
gulon
acid
would
expect
reduct
product
polysaccharid
molecul
contain
glucuron
acid
residu
termin
posit
result
tent
suggest
heparinas
endoglucuronidas
appear
cleavag
occur
region
abund
nacetyl
glucosamin
residu
portion
molecul
first
paper
state
endoglucuronidas
respons
cleavag
heparin
mastocytoma
cell
notabl
presenc
heparin
degrad
activ
report
author
alreadi
tissu
incub
rat
liver
lysosom
fraction
heparan
sulfat
result
degrad
polym
oligosaccharid
demonstr
presenc
heparan
sulfatedegrad
endoglycosidas
judg
size
oligosaccharid
repres
degrad
endproduct
limit
number
glycosid
linkag
hs
molecul
would
seem
suscept
heparitinas
phdepend
enzym
activ
ph
inact
ph
found
differ
liver
hyaluronidas
activ
ph
inact
ph
suggest
heparitinas
previous
unknown
enzym
properti
mous
melanoma
sublin
mous
melanoma
sublin
use
determin
relat
metastat
properti
abil
sublin
degrad
sulfat
glycosaminoglycan
present
ecm
cultur
vascular
endotheli
cell
highli
invas
metastat
sublin
degrad
matrix
glycosaminoglycan
faster
sublin
lower
metastat
potenti
main
product
matrix
degrad
hs
fragment
intact
cell
cellfre
homogen
high
potenti
lung
colon
degrad
purifi
hs
bovin
lung
higher
rate
cell
poor
potenti
lung
colon
analysi
degrad
fragment
indic
cell
hs
endoglycosidas
thu
abil
melanoma
cell
extravas
success
colon
lung
may
relat
capac
degrad
hs
wall
pulmonari
blood
vessel
first
studi
show
hs
endoglycosidas
associ
metastat
potenti
melanoma
cell
metastasi
clone
line
lowmetastat
tlymphoma
eb
line
highli
metastat
variant
esb
line
compar
abil
degrad
proteoglycan
subendotheli
ecm
produc
cultur
endotheli
cell
ecm
metabol
label
na
tumor
cellmedi
releas
label
degrad
product
analyz
gel
filtrat
label
materi
releas
upon
incub
esb
cell
ecm
either
expos
cover
vascular
endotheli
cell
form
lowmr
hscontain
fragment
compar
highmr
nearli
intact
sulfat
proteoglycan
releas
incub
lowmetastat
eb
cell
highand
lowmr
degrad
product
obtain
incub
ecm
serumfre
medium
condit
low
eb
high
esb
metastat
sublin
respect
highmr
proteoglycan
releas
incub
ecm
ebcondit
medium
degrad
low
mr
gag
fragment
upon
subsequ
incub
esbcondit
medium
fragment
smaller
intact
glycosaminoglycan
side
chain
releas
treatment
ecm
papain
alkalin
borohydrid
suggest
esbspecif
endoglycosidas
activ
higher
abil
esb
eb
cell
solubil
gag
scaffold
subendotheli
ecm
may
among
properti
facilit
hematogen
dissemin
extravas
first
studi
show
hs
endoglycosidas
associ
metastat
potenti
lymphoma
cell
endoglycosidas
circul
activ
lymphocyt
specif
autosensit
basic
protein
myelin
bp
penetr
blood
vessel
accumul
nervou
system
caus
experiment
autoimmun
encephalomyel
eae
investig
effector
cell
reach
target
outsid
wall
blood
vessel
studi
interact
antibp
effector
lymphocyt
basement
membranelik
ecm
produc
vascular
endotheli
cell
found
activ
rest
lymphocyt
produc
endoglycosidas
heparanas
capabl
degrad
hs
side
chain
proteoglycan
scaffold
ecm
moreov
antibp
lymphocyt
respond
bp
present
ecm
markedli
enhanc
elabor
endoglycosidas
result
suggest
tissuespecif
antigen
blood
vessel
wall
could
direct
lymphocyt
home
activ
enzym
facilit
penetr
subendotheli
basal
lamina
also
suggest
effector
lymphocyt
recogn
antigen
associ
major
histocompat
complex
signal
first
studi
describ
express
function
heparanas
activ
lymphocyt
proteas
heparanas
synergist
involv
esbmedi
degrad
ecmbound
hs
one
enzym
produc
access
substrat
next
enzym
briefli
found
degrad
hs
ecm
markedli
enhanc
presenc
plasminogen
inhibit
aprotinin
suggest
role
plasminogen
activ
pa
sequenti
degrad
ecmh
moreov
subsequ
studi
reveal
pa
activ
resid
ecm
thu
incub
plasminogen
ecm
result
plasmin
gener
heat
ecm
inactiv
abil
gener
plasmin
upon
incub
plasminogen
conclud
proteolyt
activ
express
tumor
cell
andor
resid
tumor
microenviron
ie
ecm
particip
synergist
sequenti
degrad
em
hs
sequenti
cleavag
characterist
degrad
multimolecular
structur
subendotheli
ecm
henc
detect
studi
purifi
hs
substrat
found
contain
angiogen
endotheli
cell
mitogen
basic
fibroblast
growth
factor
fgf
bound
hs
releas
cornea
treatment
heparin
hexasaccharid
heparin
fragment
hs
heparanas
find
indic
basement
membran
cornea
may
serv
physiolog
storag
depot
angiogen
molecul
abnorm
releas
growth
factor
could
respons
corneal
neovascular
varieti
ocular
diseas
suggest
sequestr
heparinbind
proangiogen
mitogen
basement
membran
liber
heparanas
might
gener
mechan
regul
access
vascular
endothelium
heparanas
play
key
role
fulfil
function
concept
ecm
reservoir
bioactiv
molecul
well
recogn
provid
strong
basi
current
appreci
tumor
microenviron
signific
support
tumor
growth
metastasi
addit
studi
proangiogen
activ
heparanas
contribut
heparanas
resid
tumor
microenviron
describ
later
key
studi
perform
clone
hpse
gene
two
manuscript
first
demonstr
heparanas
function
liber
mobil
hsbound
growth
factor
activ
underli
high
signific
enzym
promot
tumor
angiogenesi
growth
among
biolog
effect
present
studi
examin
heparanas
inhibitori
effect
nonanticoagul
speci
heparin
might
potenti
use
prevent
heparanas
mediat
extravas
bloodborn
cell
purpos
prepar
variou
speci
lowsulf
lmw
heparin
exhibit
less
anticoagul
activ
nativ
heparin
nsulfat
group
heparin
necessari
heparanas
inhibitori
activ
substitut
acetyl
group
provid
osulf
group
retain
osulf
group
could
remov
provid
n
posit
resulf
total
desulf
heparin
abolish
heparanas
inhibitori
activ
heparan
sulfat
less
potent
heparanas
inhibitor
nativ
heparin
effici
lmw
heparin
inhibit
degrad
hs
ecm
decreas
main
molecular
size
synthet
pentasaccharid
repres
bind
site
antithrombin
iii
devoid
inhibitori
activ
similar
result
obtain
heparanas
activ
releas
platelet
neutrophil
lymphoma
cell
propos
heparanas
inhibit
nonanticoagul
heparin
may
interfer
dissemin
blood
born
tumor
cell
develop
experiment
autoimmun
diseas
block
tumourcellderiv
heparanas
rat
mammari
adenocarcinoma
mat
cell
produc
hsspecif
glycosidas
heparanas
degrad
hs
sidechain
ecm
action
enzym
rather
ecmsolubil
enzym
inhibit
antimetastat
sulphat
polysaccharid
polysaccharid
fail
inhibit
metastasi
addit
experi
indic
anticoagul
activ
polysaccharid
probabl
play
minor
role
antimetastat
effect
sinc
heparin
almost
complet
deplet
heparin
molecul
anticoagul
activ
passag
antithrombin
iii
column
retain
abil
inhibit
mat
heparanas
almost
effect
unfraction
heparin
inhibit
tumourcel
metastasi
collect
data
suggest
sulphat
polysaccharid
inhibit
metastasi
mat
cell
inhibit
tumourcellderiv
heparanas
involv
penetr
vascular
endothelium
underli
basement
membran
tumour
cell
result
pave
way
develop
clinic
test
phosphomannopentaos
sulfat
muparfostat
two
studi
demonstr
heparanas
enzymat
activ
experiment
metastasi
inhibit
nonanticoagul
speci
heparin
sulfat
polysaccharid
polysaccharid
number
sulfat
polysaccharid
test
abil
inhibit
passiv
induc
experiment
allerg
encephalomyel
eae
rat
heparin
fucoidan
complet
inhibit
passiv
eae
even
treatment
begun
day
transfer
cell
pentosan
sulfat
partial
inhibitori
wherea
effect
inhibit
mere
due
kill
cell
sinc
activ
sensit
day
cell
transfer
result
earli
onset
diseas
indic
persist
transfer
cell
memori
cell
although
inhibitori
polysaccharid
anticoagul
would
appear
function
alon
reason
inhibit
sinc
heparin
prepar
devoid
anticoagul
activ
also
partial
inhibit
eae
activ
induc
eae
also
significantli
delay
treatment
heparin
result
discuss
term
polysaccharid
inhibit
enzymat
depend
movement
lymphocyt
across
central
nervou
system
vascular
endothelium
heparanaseinhibit
nonanticoagul
speci
heparin
markedli
reduc
incid
lung
metastasi
experiment
anim
low
dose
speci
heparin
also
significantli
impair
traffic
lymphocyt
suppress
cellular
immun
reactiv
experiment
autoimmun
diseas
allograft
reject
adjuv
arthriti
experiment
autoimmun
encephalomyel
abil
chemic
modifi
heparin
inhibit
immun
reaction
associ
abil
inhibit
express
lymphocyt
heparanas
relationship
anticoagul
activ
thu
heparin
devoid
anticoagul
activ
effect
regul
immun
reaction
use
appropri
dose
two
studi
demonstr
heparanas
experiment
autoimmun
diseas
inhibit
nonanticoagul
speci
heparin
sulfat
polysaccharid
depend
local
ph
migrat
lymphocyt
inflammatori
site
requir
adhes
vascular
endothelium
subendotheli
ecm
depend
local
ph
heparanas
function
either
enzym
adhes
molecul
rel
acidifi
ph
condit
heparanas
perform
enzym
degrad
hs
contrast
hydrogen
ion
concentr
quiescent
tissu
heparanas
bind
specif
hs
molecul
without
degrad
therebi
anchor
human
lymphocyt
thu
local
state
tissu
regul
activ
heparanas
determin
whether
molecul
function
enzym
proadhes
molecul
earli
articl
demonstr
heparanas
may
function
cell
adhes
molecul
activ
heparinheparan
sulfatedegrad
enzym
studi
purif
hsdegrad
enzym
human
platelet
led
discoveri
enzymat
activ
resid
least
two
member
platelet
basic
protein
pbp
famili
known
connect
tissu
activ
peptideiii
ctapiii
neutrophil
activ
pbp
ntruncat
deriv
ctapiii
neutrophil
activ
cxc
chemokin
group
molecul
involv
inflamm
wound
heal
sdspage
analysi
purifi
heparanas
result
singl
broad
band
kda
known
molecular
weight
pbp
truncat
deriv
gel
filtrat
chromatographi
heparanas
result
peak
activ
correspond
monom
dimer
tetram
ntermin
sequenc
analysi
prepar
indic
pbp
truncat
deriv
present
commerci
ctapiii
three
supplier
heparanas
activ
antisera
produc
anim
immun
ctermin
synthet
peptid
pbp
inhibit
heparanas
activ
compar
activ
purifi
enzym
presenc
preimmun
sera
enzym
determin
endoglucosaminidas
degrad
heparin
hs
optim
activ
ph
sequenc
analysi
show
two
peak
contain
ident
protein
suggest
posttransl
modif
activ
enzym
studi
character
short
glycosaminoglycan
produc
chines
hamster
ovari
cho
cell
suggest
multipl
heparanas
necessari
format
short
hs
chain
examin
whether
case
purifi
heparanas
activ
cho
cell
homogen
base
abil
bind
ionexchang
resin
elut
gelfiltr
column
four
separ
heparanas
activ
partial
purifi
four
activ
cleav
free
glycosaminoglycan
broad
ph
rang
suggest
act
endosomallysosom
pathway
size
short
hs
chain
gener
partial
purifi
heparanas
rang
kda
interestingli
four
enzym
gener
short
glycosaminoglycan
sulfaterich
modifi
domain
nonreduc
end
newli
form
chain
find
suggest
format
short
hs
glycosaminoglycan
insid
cho
cell
may
result
concert
action
multipl
heparanas
may
depend
proport
differ
enzym
environ
chain
degrad
demonstr
two
studi
sever
seriou
attempt
purifi
heparanas
enzym
yet
subsequ
studi
fail
confirm
result
purifi
heparanas
human
hepatoma
placenta
report
clone
gene
encod
enzym
express
clone
cdna
insect
mammalian
cell
yield
recombin
heparanas
protein
enzym
repres
ntermin
process
enzym
least
activ
form
heparanas
mrna
protein
preferenti
express
metastat
cell
line
specimen
human
breast
colon
liver
carcinoma
low
metastat
murin
tlymphoma
melanoma
cell
transfect
heparanas
cdna
acquir
highli
metastat
phenotyp
vivo
reflect
massiv
liver
lung
colon
repres
first
clone
mammalian
heparanas
provid
direct
evid
role
tumor
metastasi
clone
heparanas
gene
enabl
develop
specif
molecular
probe
earli
detect
treatment
cancer
metastasi
autoimmun
disord
report
cdna
sequenc
human
platelet
enzym
encod
uniqu
protein
amino
acid
identif
highli
homolog
sequenc
activ
mous
cell
highli
metastat
rat
adenocarcinoma
furthermor
express
heparanas
mrna
rat
tumor
cell
correl
metastat
potenti
exhaust
studi
shown
one
heparanas
sequenc
consist
idea
enzym
domin
endoglucuronidas
mammalian
tissu
two
paper
publish
side
side
nat
med
preced
commentari
entitl
heparanas
break
barrier
tumor
clone
function
character
long
soughtaft
heparanas
open
new
chapter
understand
potenti
manipul
metastasi
inflammatori
process
clone
gene
human
placent
cdna
librari
encod
novel
protein
exhibit
heparanas
activ
cdna
identifi
peptid
sequenc
deriv
purifi
heparanas
isol
human
hepatoma
cell
contain
open
read
frame
encod
predict
polypeptid
amino
acid
possess
put
signal
sequenc
amino
terminu
northern
blot
analysi
suggest
strong
express
placenta
spleen
transient
transfect
cell
result
express
protein
appar
molecular
mass
kda
protein
detect
condit
media
also
associ
membran
fraction
follow
cell
lysi
gene
product
shown
exhibit
heparanas
activ
specif
cleav
label
heparan
sulfat
substrat
similar
manner
purifi
nativ
protein
human
heparanas
purif
character
clone
express
report
purif
human
heparanas
embryon
fibroblast
cell
line
four
sequenti
column
chromatographi
enzym
purifi
homogen
yield
peptid
appar
molecular
mass
kda
analyz
sdspolyacrylamid
gel
electrophoresi
use
amino
acid
sequenc
ntermin
intern
heparanas
peptid
cdna
code
human
heparanas
clone
cell
stabli
transfect
pbkcmv
express
vector
contain
heparanas
cdna
show
high
heparanas
activitiy
homolog
search
reveal
homolog
protein
report
fulllength
heparanas
gene
clone
mous
embryo
cdna
librari
determin
encod
protein
amino
acid
ident
human
heparanas
fulllength
mous
gene
stabli
express
myeloma
cell
recombin
mous
heparanas
protein
purifi
homogen
cell
lysat
combin
cona
affin
chromatographi
heparin
affin
chromatographi
size
exclus
chromatographi
purifi
protein
consist
noncoval
heterodim
polypeptid
similar
human
homolog
protein
enzymat
activ
assay
use
radiolabel
ecm
hs
substrat
maximum
heparanas
activ
observ
acid
condit
howev
signific
activ
also
detect
neutral
ph
enzymat
activ
mous
heparanas
block
known
heparanas
inhibitor
see
gaskin
et
al
chap
volum
inform
heparanas
gene
clone
metastasi
paragraph
present
taken
commentari
written
dr
nakajima
boyd
respons
heparanas
gene
silenc
paper
publish
jnci
edovitski
et
al
commentari
found
suitabl
histor
review
due
high
relev
current
statu
heparanas
research
relat
question
rais
back
metastasi
subsequ
simultan
clone
cdnaencod
heparanas
goldshmidt
et
al
found
overexpress
cdnaencod
heparanas
confer
metastat
phenotyp
lymphoma
cell
nevertheless
argu
abil
increas
heparanas
level
induc
metastat
phenotyp
necessarili
impli
tumor
make
use
heparanas
drive
tumor
dissemin
subsequ
studi
edovitski
et
al
attempt
address
shortcom
use
ribozym
small
interf
rna
sirna
technolog
knock
level
endogen
heparanas
author
show
model
experiment
spontan
metastas
strategi
attenu
abil
divers
tumor
cell
includ
melanoma
mammari
adenocarcinoma
lymphoma
glioma
cell
invad
vitro
colon
distant
site
includ
liver
lung
studi
earlier
studi
perform
uno
et
al
provid
strong
support
role
heparanas
metastat
process
nevertheless
caution
taken
predict
clinic
efficaci
given
tumor
cell
remark
system
redund
mechan
effici
overcom
target
singl
molecul
redund
one
contribut
mechan
underli
lack
clinic
benefit
seen
metalloproteinas
inhibitor
cancer
patient
take
account
one
hsdegrad
endoglycosidas
identifi
redund
consid
problem
target
heparanas
compar
metalloproteinas
equal
import
issu
rais
boy
nakajima
relat
util
antiheparanas
antimetastat
therapi
cancer
treatment
concern
fact
time
present
major
patient
alreadi
dissemin
diseas
consequ
treatment
patient
antiheparanas
regimen
might
akin
close
barn
door
hors
bolt
thu
could
knockout
punch
heparanas
use
treatment
cancer
patient
least
two
option
first
increas
public
awar
cancer
screen
becom
preval
gener
popul
number
patient
diagnos
earlystag
diseas
increas
definit
tumor
still
local
therefor
amen
therapi
antimetastasi
agent
second
consid
proangiogen
effect
heparanas
first
document
edovitski
et
al
elkin
et
al
antiheparanas
drug
may
static
effect
primari
tumor
distant
tumor
lesion
prevent
establish
tumor
vasculatur
necessari
tumor
growth
beyond
mm
consider
made
compel
case
role
heparanas
tumor
progress
extent
inform
exploit
novel
therapi
depend
develop
specif
inhibitor
target
heparanas
blockad
redund
mechan
compens
loss
heparanas
cancer
statement
rightli
written
editori
gene
silenc
paper
relev
nowaday
well
gene
regul
de
mestr
et
al
report
identif
seruminduc
zinc
finger
transcript
factor
human
earli
growth
respons
gene
key
regul
induc
hpse
transcript
lymphocyt
cancer
cell
nuclear
phosphoprotein
rapidli
induc
respons
varieti
extracellular
environment
signal
includ
growth
factor
cytokin
vascular
injuri
hypoxia
studi
use
knockdown
strategi
confirm
bind
hpse
promot
vivo
play
central
role
tumor
angiogenesi
growth
metastasi
breast
bladder
colon
prostat
adenocarcinoma
support
central
role
regul
hpse
transcript
tumor
cell
gaskin
et
al
chap
volum
elkin
et
al
identifi
put
estrogen
respons
element
heparanas
promot
demonstr
function
appli
luciferas
report
gene
driven
heparanas
promot
physic
associ
estrogen
receptor
er
heparanas
promot
confirm
chip
analysi
chip
analysi
also
reveal
wild
type
inhibit
transcript
heparanas
gene
direct
bind
promot
mutat
tumorderiv
variant
lose
inhibitori
abil
case
even
regul
heparanas
gene
express
examin
seri
tumorderiv
cell
line
found
cell
exhibit
heparanas
activ
also
harbor
least
one
unmethyl
allel
cell
line
exhibit
heparanas
express
activ
found
harbor
fulli
methyl
allel
treat
cell
demethyl
agent
restor
heparanas
activ
accompani
augment
metastat
capac
vivo
cathepsin
l
play
critic
role
process
convers
latent
heparanas
activ
form
interestingli
promot
methyl
egr
famili
member
also
involv
cathepsin
l
activ
suggest
heparanas
cathepsin
l
share
regulatori
aspect
appli
tumor
model
joyc
et
al
demonstr
cathepsin
l
express
restrict
tumor
cell
major
heparanas
appear
origin
infiltr
immun
cell
thu
proheparanas
secret
one
cell
type
inflammatori
cell
activ
cathepsin
l
secret
anoth
compart
cancer
cell
cooper
drive
tumor
develop
notabl
regul
heparanas
cathepsin
l
reli
sole
gene
transcript
rather
involv
complex
regulatori
mechan
import
regulatori
element
cathepsin
l
identifi
untransl
region
utr
gene
likewis
arvatz
et
al
reveal
posttranscript
regul
heparanas
gene
express
aurich
element
gene
process
human
heparanas
precursor
evid
activ
enzym
heterodim
human
platelet
heparanas
purifi
homogen
shown
consist
two
noncoval
associ
polypeptid
chain
molecular
mass
kda
protein
sequenc
provid
basi
determin
fulllength
cdna
novel
protein
base
upon
inform
result
protein
analysi
mass
spectrometri
propos
scheme
defin
structur
organ
heparanas
relat
precursor
form
proheparanas
preproheparanas
chain
make
activ
enzym
resid
respect
nh
coohtermin
region
inact
precursor
proheparanas
heparanas
heterodim
produc
excis
loss
intern
link
segment
paper
first
suggest
human
heparanas
twochain
enzym
among
earliest
studi
demonstr
activ
enzym
heterodim
heparanas
use
psiblast
phiblast
search
sequenc
databas
similar
identifi
heparanas
member
sever
glycosyl
hydrolas
famili
glycosyl
hydrolas
clan
gha
includ
strong
local
ident
region
contain
critic
activesit
catalyt
proton
donor
nucleophil
residu
conserv
clan
enzym
furthermor
secondari
structur
predict
suggest
heparanas
like
contain
alphabeta
timbarrel
fold
common
gha
famili
base
sequenc
align
number
glycosyl
hydrolas
gha
glu
glu
human
heparanas
identifi
like
proton
donor
nucleophil
residu
respect
substitut
residu
alanin
subsequ
express
mutant
heparanas
cell
demonstr
hsdegrad
capac
abolish
contrast
alanin
substitut
two
glutam
acid
residu
glu
glu
predict
outsid
activ
site
affect
heparanas
activ
data
suggest
heparanas
member
clan
glycosyl
hydrolas
common
catalyt
mechan
involv
two
conserv
acid
residu
put
proton
donor
glu
nucleophil
glu
common
catalyt
mechan
involv
put
proton
donor
glu
nucleophil
glu
protein
initi
synthes
inact
kda
proenzym
believ
subsequ
activ
proteolyt
cleavag
gener
activ
heterodim
kda
polypeptid
analysi
seri
delet
protein
confirm
kda
subunit
essenti
enzym
activ
present
first
time
insect
cell
express
system
use
gener
larg
amount
recombin
protein
high
specif
activ
individu
subunit
clone
baculovir
secretori
vector
coexpress
insect
cell
activ
secret
heterodim
protein
recov
medium
isol
onestep
heparinsepharos
chromatographi
procedur
give
protein
puriti
recombin
enzym
behav
similarli
nativ
protein
respect
size
hs
fragment
liber
digest
substrat
cleavag
specif
prefer
acid
ph
signific
amount
activ
howev
also
detect
physiolog
ph
valu
measur
vitro
assay
vivo
degrad
cellbound
hs
link
disulfid
bond
format
activ
heparanas
human
tumor
cell
investig
mass
spectrometri
analysi
heparanas
purifi
condit
medium
human
fibrosarcoma
cell
reveal
two
disulfid
bond
one
scysteinyl
residu
shown
although
format
bond
scysteinyl
littl
effect
heparanas
function
disulfid
bond
necessari
secret
activ
heparanas
thu
present
find
provid
basi
refin
heparanas
structur
studi
develop
novel
heparanas
inhibitor
gener
antibodi
preferenti
recogn
activ
kda
heparanas
form
compar
nonact
kda
heparanas
precursor
util
antiheparanas
antibodi
studi
cellular
local
latent
kda
activ
kda
heparanas
form
uptak
process
exogen
ad
heparanas
interestingli
process
kda
also
kda
heparanas
precursor
local
perinuclear
vesicl
suggest
heparanas
process
occur
lysosom
inde
heparanas
process
complet
inhibit
chloroquin
bafilomycin
inhibitor
lysosom
proteas
similarli
process
membranetarget
heparanas
also
chloroquinesensit
rule
plasma
membran
heparanas
process
site
final
provid
evid
antibodi
partial
neutral
enzymat
activ
heparanas
suggest
ntermin
region
molecul
involv
assum
activ
conform
earli
paper
local
heparanas
late
endosom
lysosom
appli
cathepsin
l
knockout
tissu
cultur
fibroblast
well
cathepsin
l
gene
silenc
overexpress
strategi
demonstr
remov
linker
peptid
convers
proheparanas
activ
form
brought
predominantli
cathepsin
l
excis
acid
peptid
locat
c
terminu
linker
segment
two
function
cathepsin
l
cleavag
site
critic
activ
proheparanas
mass
spectrometri
reveal
entir
linker
segment
suscept
multipl
endocleavag
cathepsin
l
activ
subunit
gener
sever
altern
adjac
endocleavag
yield
precis
subunit
andor
slightli
elong
form
altogeth
mode
action
present
demonstr
process
activ
proheparanas
brought
sole
cathepsin
l
result
corrobor
earlier
public
group
entitl
sitedirect
mutagenesi
proteolyt
cleavag
activ
human
proheparanas
present
among
aspect
predict
structur
model
heparanas
protein
includ
kda
peptid
linker
segment
hinder
access
hs
substrat
activ
site
enzym
henc
inhibit
heparanas
enzymat
activ
wu
al
present
crystal
structur
human
hpse
resolut
reveal
endoact
bind
cleft
expos
proteolyt
activ
latent
prohps
use
oligosaccharid
complex
map
substratebind
sulfaterecognit
motif
data
shed
light
structur
interact
key
enzym
involv
ecm
mainten
provid
start
point
design
hpse
inhibitor
use
biochem
tool
anticanc
therapeut
resolut
heparanas
crystal
structur
relat
studi
entitl
activitybas
probe
function
interrog
retain
group
report
activ
supposedli
inact
heparanas
proenzym
label
activitybas
abp
probe
lead
surpris
insight
regard
structur
relationship
proheparanas
matur
heparanas
bacteri
homolog
see
wu
davi
chap
volum
inform
heparanas
structur
properti
see
gaskin
et
al
chap
volum
inform
heparanas
gene
regul
clone
character
human
gene
promot
role
gabind
protein
regul
basal
promot
activ
understand
mechan
gene
express
regul
first
map
transcript
start
site
heparanas
gene
found
mrna
transcrib
nucleotid
posit
bp
upstream
atg
codon
promot
region
gene
clone
sequenc
analysi
reveal
tataless
gcrich
promot
gene
belong
famili
housekeep
gene
promot
region
exhibit
strong
promot
activ
two
thyroid
tumor
cell
line
truncat
analysi
promot
identifi
minim
region
strong
basal
promot
activ
truncat
mutat
analysi
promot
reveal
three
site
four
etsrelev
element
ere
significantli
contribut
basal
promot
activ
bind
site
ere
site
gabind
protein
gabp
confirm
electrophoret
mobil
shift
assay
competit
supershift
electrophoret
mobil
shift
assay
cotransfect
spand
gabpdefici
drosophila
cell
promoterdriven
luciferas
construct
plu
express
vector
encod
gabp
gene
induc
luciferas
gene
express
mutat
truncat
ere
site
reduc
luciferas
express
cell
thyroid
tumor
cell
line
coexpress
gabpalphabeta
increas
luciferas
report
gene
express
result
collect
suggest
cooper
gabp
regul
promot
activ
character
human
heparanas
gene
promot
demonstr
cooper
gabp
regul
heparanas
promot
activ
identifi
four
put
estrogen
respons
element
heparanas
promot
region
found
transcript
luciferas
report
gene
driven
heparanas
promot
significantli
increas
estrogenreceptor
posit
human
breast
carcinoma
cell
estrogen
treatment
estrogeninduc
heparanas
mrna
transcript
estrogen
receptorposit
estrogen
receptorneg
breast
cancer
cell
confirm
promot
studi
data
estrogen
effect
heparanas
mrna
express
level
abolish
presenc
pure
antiestrogen
ici
indic
classic
estrogen
receptor
pathway
involv
transcript
activ
heparanas
vivo
exposur
estrogen
augment
level
heparanas
protein
cell
embed
matrigel
plug
correl
increas
plug
vascular
collect
data
suggest
new
molecular
pathway
estrogen
independ
prolif
effect
may
induc
heparanas
overexpress
thu
promot
tumorstrom
interact
critic
breast
carcinoma
develop
progress
estrogen
induc
heparanas
overexpress
thu
promot
tumorstrom
interact
gene
investig
epigenet
regul
heparanas
locu
methylationspecif
bisulfit
pcr
perform
panel
human
cancer
cell
line
cytosin
methyl
heparanas
promot
associ
inactiv
affect
allel
despit
lack
sequenc
homolog
extens
methyl
cpg
island
found
human
choriocarcinoma
jar
rat
glioma
cell
lack
heparanas
activ
treatment
cell
demethyl
agent
result
stabl
doseand
timedepend
promot
hypomethyl
accompani
reappear
heparanas
mrna
protein
enzymat
activ
inhibitor
histon
deacetylas
trichostatin
fail
induc
either
effect
upregul
heparanas
express
activ
demethyl
drug
associ
mark
increas
lung
colon
pretreat
rat
glioma
cell
increas
metastat
potenti
vivo
inhibit
mice
treat
laminaran
sulfat
potent
inhibitor
heparanas
activ
propos
model
wherein
express
mammalian
heparanas
gene
modul
interplay
transactiv
genet
cisinhibitori
epigenet
element
promot
hypothes
promot
cpg
hypomethyl
increas
express
could
determin
heparanas
express
pathogenesi
bladder
cancer
bladder
cancer
cell
line
significantli
restor
heparanas
express
treatment
transfect
sirna
bladder
cancer
cell
line
significantli
downregul
heparanas
express
compar
control
sirna
transfect
bladder
cancer
pair
normal
bladder
sampl
heparanas
express
significantli
higher
bladder
cancer
normal
bladder
p
perform
methylationspecif
pcr
target
cpg
site
within
corebind
consensu
motif
ggcg
gggcgg
methyl
preval
significantli
higher
normal
bladder
bladder
cancer
p
invers
correl
heparanas
express
p
total
seri
bladder
cancer
normal
bladder
sampl
combin
promot
cpg
methyl
express
regul
heparanas
express
stepwis
manner
heparanas
express
lowest
methylationposit
sampl
highest
methylationneg
sampl
first
studi
demonstr
increas
heparanas
express
pathogenesi
bladder
cancer
due
promot
hypomethyl
transcript
factor
identifi
transcript
factor
earli
growth
respons
gene
key
regul
induc
heparanas
transcript
cell
use
chromatin
immunoprecipit
demonstr
first
time
bind
heparanas
gene
promot
vivo
import
question
role
regul
heparanas
transcript
tumor
cell
assess
studi
carri
four
epitheli
tumor
line
differ
tissu
origin
function
dissect
heparanas
promot
identifi
region
critic
transcript
heparanas
gene
transactiv
studi
use
express
vector
cotransfect
report
construct
contain
region
show
heparanas
promot
activ
dosedepend
manner
prostat
breast
adenocarcinoma
colon
carcinoma
cell
line
contrast
overexpress
result
dosedepend
repress
promot
activ
melanoma
cell
use
sitedirect
mutagenesi
region
found
contain
two
function
site
electrophoret
mobil
shift
assay
show
bind
site
upon
activ
tumor
cell
furthermor
heparanas
promot
region
contain
site
also
induc
tumor
cell
induct
correspond
hpse
express
level
studi
show
regul
heparanas
transcript
tumor
cell
importantli
repress
activ
role
depend
tumor
type
two
studi
indic
heparanas
gene
express
due
promot
hypomethyl
interact
transcript
factor
demonstr
wildtyp
wt
bind
heparanas
promot
inhibit
activ
wherea
mutant
variant
fail
exert
inhibitori
effect
moreov
mutant
even
activ
heparanas
promot
activ
elimin
inhibit
sever
cell
type
result
signific
increas
heparanas
gene
express
enzymat
activ
trichostatin
abolish
inhibitori
effect
wt
suggest
involv
histon
deacetyl
neg
regul
heparanas
promot
altogeth
result
indic
heparanas
gene
regul
normal
condit
mutat
inactiv
cancer
develop
lead
induct
heparanas
express
provid
possibl
explan
frequent
increas
heparanas
level
observ
cours
tumorigenesi
wildtyp
bind
heparanas
promot
inhibit
activ
purpos
current
studi
identifi
mechan
respons
heparanas
induct
provid
evid
heparanas
express
regul
posttranscript
level
sequenc
untransl
region
utr
gene
construct
utr
immedi
follow
heparanas
cdna
reduc
heparanas
enzymat
activ
protein
level
result
decreas
cellular
invas
capac
identifi
sequenc
within
utr
mediat
heparanas
downregul
character
adenin
uracil
u
rich
consensu
element
within
region
delet
entir
region
elimin
inhibitori
effect
utr
result
elev
heparanas
level
format
larger
tumor
xenograft
indistinguish
produc
heparanaseoverexpress
cell
term
size
vascular
akt
activ
result
suggest
loss
import
regulatori
mechan
contribut
heparanas
induct
human
cancer
heparanas
express
regul
posttranscript
level
sequenc
untransl
region
utr
gene
heparanas
heparanas
hpse
potent
protumorigen
proangiogen
prometastat
enzym
overexpress
brain
metastat
breast
cancer
bmbc
hypothes
hpse
gene
express
might
regul
micro
rna
might
exploit
therapeut
use
mir
rnahybrid
identifi
candid
micro
rna
may
directli
target
hpse
suppress
bmbc
found
level
invers
correl
heparanas
express
enzymat
activ
cancer
cell
metastat
propens
lowest
highli
aggress
bmbc
cell
variant
compar
either
nontumorigen
nonmetastat
human
mammari
epitheli
cell
find
valid
analys
heparanas
content
pair
clinic
specimen
normal
mammari
gland
versu
invas
ductal
carcinoma
primari
breast
cancer
versu
bmbc
regulatori
experi
inhibit
express
activ
heparanas
bmbc
cell
wherea
modul
heparanas
block
phenotyp
effect
function
experi
stabl
express
bmbc
cell
inhibit
heparanas
vitro
cell
invas
experiment
brain
metastasi
togeth
find
illustr
micro
rna
mechan
link
brain
metastat
breast
cancer
heparanas
control
offer
strong
rational
develop
heparanasebas
therapeut
treatment
cancer
patient
brain
metastas
bmbc
particular
graftversushost
diseas
gvhd
common
caus
nonrelaps
mortal
morbid
hematopoiet
stem
cell
transplant
hsct
welldocu
involv
heparanas
process
inflamm
autoimmun
led
us
investig
associ
hpse
gene
singlenucleotid
polymorph
snp
risk
gvhd
present
studi
indic
highli
signific
correl
hpse
gene
snp
combin
risk
develop
acut
gvhd
moreov
studi
reveal
discrep
recipi
donor
snp
may
elev
significantli
risk
acut
gvhd
associ
statist
signific
recipi
possess
genotyp
combin
dictat
higher
level
heparanas
compar
human
leukocyt
antigen
hla
match
donor
addit
hpse
gene
snp
disclos
correl
extens
chronic
gvhd
nonrelaps
mortal
overal
surviv
studi
indic
involv
heparanas
develop
acut
extens
chronic
gvhd
moreov
suggest
possibl
mechan
aggress
behavior
lymphocyt
lead
gvhd
recipi
possess
genotyp
combin
dictat
high
level
heparanas
mrna
compar
hlamatch
donor
express
low
level
heparanas
see
ostrovski
et
al
chap
volum
inform
heparanas
gene
snp
heparanas
mediat
angiogenesi
mode
action
demonstr
heparanas
intim
involv
angiogenesi
elucid
mode
action
apart
direct
involv
ecm
degrad
ec
migrat
heparanas
releas
activ
bfgf
subendotheli
ecm
well
bfgfstimul
hs
degrad
fragment
ec
surfac
interestingli
ecmderiv
hs
fragment
induc
littl
potenti
growthpromot
activ
bfgf
angiogen
effect
heparanas
demonstr
vivo
matrigel
plug
assay
show
threeto
four
fold
increas
neovascular
induc
murin
tlymphoma
cell
stabl
transfect
heparanas
gene
increas
tissu
vascular
also
observ
mous
woundheal
model
respons
topic
administr
recombin
heparanas
immunohistochem
stain
human
colon
carcinoma
tissu
reveal
high
express
heparanas
protein
endothelium
sprout
capillari
small
vessel
matur
quiescent
blood
vessel
abil
heparanas
promot
tumor
angiogenesi
involv
tumor
metastasi
make
promis
target
cancer
therapi
earli
studi
demonstr
abil
heparanas
promot
tumor
angiogenesi
present
studi
emphas
import
cell
surfac
express
secret
heparanas
tumor
angiogenesi
metastasi
purpos
nonmetastat
eb
mous
lymphoma
cell
transfect
predominantli
intracellular
human
heparanas
readili
secret
chimer
construct
compos
human
enzym
chicken
heparanas
signal
peptid
eb
cell
overexpress
secret
heparanas
invad
reconstitut
basement
membran
much
higher
extent
cell
overexpress
intracellular
enzym
cell
invas
inhibit
presenc
laminaran
sulfat
potent
inhibitor
heparanas
activ
experiment
metastasi
increas
invas
vitro
reflect
vivo
rapid
massiv
liver
colon
acceler
mortal
fact
mice
inocul
cell
express
secret
enzym
succumb
liver
metastasi
dysfunct
earli
day
sc
inocul
cell
tumor
burden
exceed
bodi
weight
cell
surfac
local
secret
heparanas
markedli
stimul
tumor
angiogenesi
demonstr
increas
vessel
densiti
function
evalu
mri
tumor
produc
cell
express
secret
vs
nonsecret
heparanas
consist
actual
count
blood
vessel
altogeth
result
indic
potent
proangiogen
prometastat
properti
heparanas
tightli
regul
cellular
local
secret
increas
potenc
secret
enzym
make
promis
target
anticanc
drug
develop
heparanas
gene
silenc
tumor
invas
angiogenesi
metastasi
studi
perform
prior
hpse
gene
clone
sought
determin
role
heparanas
tumor
progress
howev
investig
reli
use
heparinmimick
molecul
inhibit
heparanas
activ
reagent
use
previou
studi
lack
specif
conclus
drawn
studi
somewhat
debat
edovitski
et
al
appli
ribozym
small
interf
rna
sirna
technolog
knock
level
endogen
heparanas
author
convincingli
show
model
experiment
spontan
metastas
strategi
attenu
abil
divers
tumor
cell
includ
melanoma
mammari
adenocarcinoma
lymphoma
glioma
cell
invad
vitro
colon
distant
site
includ
liver
lung
result
provid
strong
support
role
heparanas
metastat
process
moreov
studi
use
ration
develop
antiheparanas
strategi
cancer
patient
descript
taken
commentari
written
boyd
nakajima
report
heparanas
stimul
tissu
factor
tf
express
endotheli
cancer
cell
result
elev
coagul
activ
hypothes
heparanas
regul
coagul
modul
found
heparanas
overexpress
exogen
addit
stimul
tissu
factor
pathway
inhibitor
tfpi
express
fold
tfpi
accumul
cell
cultur
medium
exceed
magnitud
observ
induct
tfpi
gene
transcript
reach
sixfold
increas
extracellular
accumul
tfpi
correl
increas
coagul
activ
effect
found
independ
heparanas
enzymat
activ
interact
hs
correl
reduc
tfpi
level
cell
surfac
interact
heparanas
tfpi
evid
coimmunoprecipit
result
tfpi
displac
surfac
vascular
endothelium
thu
heparanas
facilit
blood
coagul
cell
surfac
two
independ
mechan
dissoci
tfpi
vascular
surfac
shortli
local
elev
heparanas
level
subsequ
induct
tf
express
see
nadir
chap
volum
inform
heparanas
coagul
system
gener
homozyg
transgen
mice
hpatg
overexpress
human
heparanas
tissu
character
involv
enzym
tissu
morphogenesi
vascular
energi
metabol
biochem
analysi
hs
isol
newborn
mice
adult
tissu
reveal
profound
decreas
size
hs
chain
deriv
hpatg
vs
control
mice
despit
mice
appear
normal
fertil
exhibit
normal
life
span
signific
increas
number
implant
embryo
note
hpatg
vs
control
mice
overexpress
heparanas
result
increas
level
urinari
protein
creatinin
suggest
effect
kidney
function
reflect
also
electron
microscopi
examin
kidney
tissu
hpatg
mice
exhibit
reduc
food
consumpt
bodi
weight
compar
control
mice
effect
heparanas
tissu
remodel
morphogenesi
best
demonstr
phenotyp
hpatg
mammari
gland
show
excess
branch
widen
duct
associ
enhanc
neovascular
disrupt
epitheli
basement
membran
hpatg
mice
exhibit
acceler
rate
hair
growth
correl
high
express
heparanas
hair
follicl
keratinocyt
increas
vascular
hpatg
liver
show
excess
heparanas
overexpress
hspg
turnov
acceler
along
upregul
hs
nand
osulf
thu
yield
heparinlik
chain
without
domain
structur
typic
hs
heparanas
overexpress
mous
organ
human
tumor
correl
increas
hs
wherea
domain
structur
conserv
heavili
sulfat
hs
fragment
strongli
promot
format
ternari
complex
fibroblast
growth
factor
fgf
receptor
heparanas
thu
contribut
regul
hs
biosynthesi
way
may
promot
growth
factor
action
tumor
angiogenesi
metastasi
report
target
disrupt
murin
heparanas
gene
elimin
heparanas
enzymat
activ
result
accumul
long
hs
chain
unexpectedli
heparanas
knockout
hpseko
mice
fertil
exhibit
normal
life
span
show
promin
patholog
alter
lack
major
abnorm
attribut
mark
elev
express
matrix
metalloproteinas
primarili
compens
lack
heparanas
coregul
heparanas
mmp
also
note
mark
decreas
mmp
primarili
express
follow
transfect
overexpress
heparanas
gene
cultur
human
mammari
carcinoma
cell
gener
viabl
hpseko
mice
lack
signific
abnorm
may
provid
promis
indic
use
heparanas
target
drug
develop
studi
constitut
heparanasedefici
hpse
mice
gener
background
use
creloxp
recombin
system
complet
lack
heparanas
mrna
protein
activ
although
heparanas
implic
embryogenesi
develop
hpse
mice
anatom
normal
fertil
interestingli
traffick
dendrit
cell
skin
drain
lymph
node
markedli
reduc
hpse
mice
furthermor
abil
hpse
mice
gener
allerg
inflammatori
respons
airway
process
requir
dendrit
cell
migrat
also
impair
find
establish
import
role
heparanas
immun
identifi
enzym
potenti
target
regul
immun
respons
four
studi
describ
gener
properti
heparanas
overexpress
knockout
mice
proteoglycan
provid
evid
hs
substrat
also
regul
heparanas
addit
heparin
xylosid
cell
cultur
result
pronounc
accumul
heparanas
cultur
medium
wherea
sodium
chlorat
effect
moreov
cellular
uptak
heparanas
markedli
reduc
hsdefici
mutant
cell
heparan
sulfat
proteoglycandefici
colon
cancer
cell
heparinasetr
cell
notabl
heparanas
resid
endosomallysosom
compart
rel
long
period
time
like
play
role
normal
turnov
hs
coloc
studi
cell
fraction
follow
heparanas
addit
identifi
syndecan
famili
member
candid
molecul
respons
heparanas
uptak
provid
effici
mechan
limit
extracellular
accumul
function
heparanas
first
paper
describ
syndecanmedi
cellular
uptak
heparanas
protumorigen
properti
heparanas
found
mediat
part
proautophag
function
demonstr
tumor
xenograft
model
human
cancer
use
inhibitor
lysosom
chloroquin
heparanas
alon
combin
notabl
heparanaseoverexpress
cell
resist
stress
chemotherapi
manner
associ
increas
autophagi
effect
revers
chloroquin
treatment
collect
result
establish
role
heparanas
modul
autophagi
normal
malign
cell
therebi
confer
growth
advantag
stress
well
resist
chemotherapi
first
paper
describ
role
heparanas
autophagi
emerg
evid
indic
exosom
play
key
role
tumorhost
crosstalk
exosom
secret
composit
function
capac
alter
tumor
progress
aggress
phenotyp
discov
human
cancer
cell
myeloma
lymphoblastoid
breast
cancer
express
heparanas
enhanc
tumor
cell
expos
exogen
heparanas
exosom
secret
dramat
increas
heparanas
enzym
activ
requir
robust
enhanc
exosom
secret
enzymat
inact
form
heparanas
dramat
increas
exosom
secret
heparanas
also
impact
exosom
protein
cargo
reflect
higher
level
vegf
hepatocyt
growth
factor
exosom
secret
heparanasehigh
express
cell
compar
heparanaselow
express
cell
function
assay
exosom
heparanasehigh
cell
stimul
spread
tumor
cell
fibronectin
invas
endotheli
cell
ecm
better
exosom
secret
heparanaselow
cell
studi
reveal
heparanas
help
drive
exosom
secret
alter
exosom
composit
facilit
product
exosom
impact
tumor
host
cell
behavior
therebi
promot
tumor
progress
show
syndecan
control
biogenesi
exosom
interact
endosomalsort
complex
requir
transport
accessori
compon
alix
investig
role
heparanas
syndecansynteninalix
exosom
biogenesi
pathway
find
identifi
heparanas
modul
syndecansynteninalix
pathway
foster
endosom
membran
bud
biogenesi
exosom
trim
heparan
sulfat
chain
syndecan
addit
data
suggest
mechan
control
select
specif
cargo
exosom
report
heparanas
tailor
syndecan
exosom
product
suggest
upregul
syntenin
heparanas
cancer
may
support
suspect
role
exosom
tumor
biolog
investig
impact
antimyeloma
drug
exosom
biogenesi
myeloma
cell
expos
commonli
util
antimyeloma
drug
bortezomib
carfilzomib
melphalan
exosom
secret
cell
dramat
enhanc
chemotherapyinduc
exosom
chemoexosom
proteom
profil
distinct
cell
expos
drug
includ
dramat
elev
level
heparanas
present
exosom
cargo
heparanas
present
exosom
surfac
capabl
degrad
heparan
sulfat
embed
within
ecm
expos
myeloma
cell
chemoexosom
transfer
heparanas
cargo
cell
enhanc
hs
degrad
activ
lead
activ
erk
signal
increas
shed
proteoglycan
exposur
chemoexosom
macrophag
enhanc
secret
import
myeloma
growth
factor
moreov
chemoexosom
stimul
macrophag
migrat
effect
block
monoclon
antibodi
inhibit
heparanas
enzymat
activ
data
suggest
antimyeloma
therapi
ignit
burst
exosom
high
level
heparanas
remodel
ecm
alter
tumor
host
cell
behavior
like
contribut
chemoresist
eventu
patient
relaps
heparanas
act
master
regul
aggress
tumor
phenotyp
part
enhanc
express
protein
known
drive
tumor
progress
eg
vegf
hepatocyt
growth
factor
hgf
rankl
howev
mechan
wherebi
enzym
regul
gene
express
remain
unknown
previous
report
elev
heparanas
level
myeloma
cell
caus
dramat
reduct
amount
nucleu
hs
shown
inhibit
activ
histon
acetyltransferas
hat
enzym
vitro
hypothes
reduct
nuclear
cell
express
high
level
heparanas
would
result
increas
hat
activ
lead
stimul
protein
transcript
found
myeloma
cell
tumor
express
high
level
heparanas
low
level
nuclear
significantli
higher
level
hat
activ
compar
cell
tumor
express
low
level
heparanas
high
level
hat
activ
heparanasehigh
cell
block
inhibitor
heparanas
restor
high
level
heparanasehigh
cell
diminish
nuclear
hat
activ
establish
potent
inhibitor
hat
exposur
heparanasehigh
cell
anacard
acid
inhibitor
hat
activ
significantli
suppress
express
vegf
two
gene
known
upregul
follow
elev
heparanas
result
reveal
novel
mechanist
pathway
driven
heparanas
express
lead
decreas
nuclear
increas
hat
activ
upregul
transcript
multipl
gene
drive
aggress
tumor
phenotyp
methyl
histon
fundament
epigenet
process
regul
gene
express
program
mammalian
cell
report
unexpect
find
heparanas
enter
nucleu
activ
human
lymphocyt
regul
transcript
cohort
induc
immun
respons
gene
control
histon
h
methyl
pattern
found
nuclear
heparanas
preferenti
associ
euchromatin
genomewid
chiponchip
analys
show
heparanas
recruit
promot
transcrib
region
distinct
cohort
transcript
activ
gene
knockdown
overexpress
heparanas
gene
also
show
chromatinbound
heparanas
prerequisit
transcript
subset
induc
immun
respons
gene
activ
cell
furthermor
action
heparanas
seem
influenc
gene
transcript
associ
demethylas
prevent
recruit
methylas
mll
therebi
modifi
histon
h
methyl
pattern
data
indic
heparanas
belong
emerg
class
protein
play
import
role
regul
transcript
addit
wellrecogn
extranuclear
function
examin
possibl
heparanas
directli
particip
vegf
gene
regul
provid
evid
heparanas
overexpress
human
embryon
kidney
human
breast
carcinoma
rat
glioma
cell
result
sixfold
increas
vegf
protein
mrna
level
correl
elev
phosphoryl
moreov
heparanas
downregul
mous
melanoma
cell
specif
sirna
vector
accompani
decreas
vegf
phosphoryl
level
suggest
vegf
gene
express
regul
endogen
heparanas
interestingli
specif
inhibitor
attenu
vegf
upregul
heparanas
wherea
src
inhibitor
complet
abrog
effect
result
indic
heparanas
activ
involv
regul
vegf
gene
express
mediat
activ
src
famili
member
first
paper
heparanas
vegf
gene
express
mediat
heparanas
signal
heparanas
exert
biolog
function
appar
independ
enzymat
activ
enhanc
phosphoryl
select
protein
kinas
induc
gene
transcript
predict
threedimension
structur
constitut
activ
heparanas
clearli
delin
timbarrel
fold
previous
anticip
enzym
interestingli
model
also
reveal
exist
coohtermin
domain
cdomain
appar
integr
part
timbarrel
fold
provid
evid
cdomain
critic
heparanas
enzymat
activ
secret
moreov
cdomain
found
mediat
nonenzymat
function
heparanas
facilit
akt
phosphoryl
cell
prolifer
tumor
xenograft
progress
find
support
notion
heparanas
exert
enzymat
activityindepend
function
identifi
first
time
protein
domain
respons
heparanasemedi
signal
inhibitor
direct
cdomain
combin
inhibitor
heparanas
enzymat
activ
expect
neutral
heparanas
function
profoundli
affect
tumor
growth
angiogenesi
metastasi
provid
evid
enzymat
activ
inact
heparanas
enhanc
epiderm
growth
factor
receptor
egfr
phosphoryl
enhanc
egfr
phosphoryl
associ
increas
cell
migrat
cell
prolifer
coloni
format
attenu
src
inhibitor
similarli
heparanas
gene
silenc
mean
sirna
associ
reduc
src
egfr
phosphoryl
level
decreas
cell
prolifer
moreov
heparanas
express
correl
increas
phosphoegfr
level
progress
head
neck
carcinoma
provid
strong
clinic
support
egfr
modul
heparanas
thu
heparanas
seem
modul
two
critic
system
involv
tumor
progress
name
vegf
express
egfr
activ
neutral
heparanas
enzymat
nonenzymat
function
therefor
expect
profoundli
affect
tumor
growth
angiogenesi
metastasi
first
paper
describ
involv
heparanas
epiderm
growth
factor
receptor
egfr
phosphoryl
enzym
also
shown
induc
stat
phosphoryl
develop
conveni
assay
base
cleavag
synthet
heparin
oligosaccharid
fondaparinux
assay
measur
appear
disaccharid
product
heparanasecatalyz
fondaparinux
cleavag
colorimetr
use
tetrazolium
salt
assay
homogen
substrat
singl
point
cleavag
kinet
enzym
reliabl
character
give
k
microm
k
cat
fondaparinux
substrat
inhibit
heparanas
publish
inhibitor
also
studi
k
nm
determin
simplic
robust
method
greatli
assist
routin
assay
heparanas
activ
also
could
adapt
highthroughput
screen
compound
librari
data
gener
directli
compar
across
studi
colorimetr
assay
use
screen
heparanaseinhibit
molecul
heparanas
mrna
protein
express
increas
neoplast
stage
progress
unfold
mous
model
multistag
pancreat
islet
carcinogenesi
notabl
heparanas
deliv
neoplast
lesion
larg
part
infiltr
innat
immun
cell
sulfat
oligosaccharid
mimet
hs
mupafostat
use
inhibit
simultan
heparanas
activ
hs
effector
function
signific
effect
distinct
stage
tumorigenesi
produc
reduct
number
earli
progenitor
lesion
impair
tumor
growth
later
stage
respons
associ
decreas
cell
prolifer
increas
apoptosi
impair
angiogenesi
substant
reduct
number
invas
carcinoma
addit
show
reduct
tumor
angiogenesi
correl
reduc
associ
vegfa
receptor
tumor
endothelium
implic
heparanas
mobil
matrixassoci
vegf
data
encourag
clinic
applic
inhibitor
mani
human
cancer
heparanas
express
elev
mobil
hsbind
regulatori
factor
implic
abil
glycolsplit
heparin
roneparstat
inhibit
growth
myeloma
tumor
assess
use
multipl
anim
model
divers
panel
human
murin
myeloma
cell
line
effect
inhibit
myeloma
growth
vivo
even
confront
aggress
grow
tumor
within
human
bone
addit
treatment
caus
chang
within
tumor
consist
compound
abil
inhibit
heparanas
includ
downregul
hgf
vegf
express
suppress
angiogenesi
also
diminish
heparanaseinduc
shed
inhibit
heparanasemedi
degrad
hs
side
chain
thu
confirm
antiheparanas
activ
compound
combin
dexamethason
block
tumor
growth
vivo
presum
dual
target
tumor
microenviron
see
noseda
barberi
chap
volum
inform
roneparstat
model
hs
mimet
pixatimod
shown
inhibit
angiogenesi
vivo
induc
antitumour
antimetastat
effect
murin
model
breast
prostat
liver
lung
colon
head
neck
cancer
melanoma
enhanc
antitumour
activ
also
note
use
combin
sorafenib
liver
cancer
model
pk
data
reveal
halflif
rel
long
pharmacolog
relev
concentr
radiolabel
observ
liver
tumour
antimetastat
properti
like
due
inhibit
heparanas
may
prove
critic
attribut
compound
enter
phase
clinic
trial
prolifer
invas
capac
vivo
tumor
growth
level
heparanas
hpse
pediatr
brain
tumor
higher
healthi
brain
tissu
treatment
pediatr
brain
tumor
cell
hpse
stimul
growth
notabl
latent
form
hpse
enhanc
cell
viabil
rapidli
activ
erk
akt
signal
pathway
enzymat
activ
hpse
detect
hpse
inhibitor
effici
kill
pediatr
brain
tumor
cell
normal
human
astrocyt
compound
also
reduc
tumor
cell
invas
vitro
potent
reduc
size
flank
tumor
vivo
result
indic
hpse
malign
brain
tumor
affect
tumor
cell
ecm
see
chapter
karinforsbergnillson
inform
heparanas
glioma
mesothelioma
tumor
growth
markedli
attenu
heparanas
gene
silenc
heparanas
inhibitor
defibrotid
mark
increas
surviv
mesotheliomabear
mice
record
heparanas
inhibitor
potent
vivo
convent
chemotherapi
clinic
heparanas
level
patient
pleural
effus
could
distinguish
malign
benign
effus
heparanas
hscore
associ
reduc
patient
surviv
given
preclin
clinic
data
heparanas
appear
import
mediat
mesothelioma
heparanas
inhibitor
worthi
investig
new
therapeut
modal
mesothelioma
clinic
trial
use
scid
mous
model
demonstr
enhanc
express
heparanas
myeloma
cell
dramat
upregul
spontan
metastasi
bone
occur
primari
tumor
grow
subcutan
also
primari
tumor
establish
bone
interestingli
tumor
form
subcutan
inject
cell
metastas
bone
also
site
includ
spleen
liver
lung
contrast
tumor
form
inject
cell
directli
bone
exhibit
restrict
pattern
metastasi
includ
dissemin
tumor
bone
extramedullari
site
addit
express
heparanas
myeloma
cell
acceler
initi
growth
primari
tumor
increas
wholebodi
tumor
burden
compar
control
enhanc
number
size
microvessel
within
primari
tumor
studi
indic
heparanas
critic
determin
myeloma
dissemin
growth
vivo
use
affymetrix
microarray
show
gene
encod
heparanas
hpse
express
myeloma
cell
line
hmcl
hspe
posit
hmcl
gene
express
product
solubl
significantli
increas
knockdown
hpse
sirna
result
decreas
gene
express
solubl
product
without
affect
membran
express
thu
hpse
influenc
express
shed
contrari
hmcl
hpse
express
primari
mmc
sampl
wherea
express
bone
marrow
bm
microenviron
sampl
latter
hpse
express
median
level
polymorphonuclear
cell
cell
highli
express
monocyt
osteoclast
affymetrix
data
valid
protein
level
hmcl
patient
sampl
report
gene
express
mainli
bm
environ
ie
hspe
associ
shorter
eventfre
surviv
patient
newli
diagnos
myeloma
treat
highdos
chemotherapi
stem
cell
transplant
studi
suggest
clinic
inhibitor
hpse
could
benefici
patient
mm
order
explor
mechan
underli
protumorigen
capac
heparanas
establish
induc
teton
system
heparanas
express
markedli
increas
follow
addit
doxycyclin
dox
cultur
medium
cag
human
myeloma
cell
infect
induc
heparanas
gene
construct
result
increas
coloni
number
size
soft
agar
moreov
tumor
xenograft
produc
cagheparanas
cell
markedli
increas
mice
supplement
dox
drink
water
compar
control
mice
maintain
without
dox
consist
found
heparanas
induct
associ
decreas
level
suggest
chemokin
exert
tumorsuppressor
properti
myeloma
inde
recombin
attenu
prolifer
cag
myeloma
cell
similarli
attenu
prolifer
human
umbil
vein
endotheli
cell
impli
exhibit
antiangiogen
capac
strikingli
develop
tumor
xenograft
produc
cagheparanas
cell
overexpress
markedli
reduc
compar
control
cell
moreov
tumor
growth
significantli
attenu
mice
inocul
human
mous
myeloma
cell
treat
fusion
protein
indic
function
potent
antimyeloma
cytokin
discov
drug
use
treatment
myeloma
upregul
heparanas
express
frontlin
antimyeloma
drug
bortezomib
carfilzomib
activ
pathway
trigger
heparanas
express
tumor
cell
block
pathway
diminish
chemotherapyinduc
upregul
heparanas
express
activ
signal
also
found
drive
high
heparanas
express
drug
resist
myeloma
cell
line
addit
enhanc
heparanas
express
chemotherapi
also
caus
releas
heparanas
tumor
cell
condit
medium
solubl
heparanas
taken
macrophag
trigger
increas
product
heparanas
also
taken
tumor
cell
induc
express
hgf
vegf
activ
erk
akt
signal
pathway
chang
induc
heparanas
known
associ
promot
aggress
tumor
phenotyp
importantli
heparanas
inhibitor
roneparstat
diminish
uptak
downstream
effect
solubl
heparanas
togeth
discoveri
reveal
novel
mechan
wherebi
chemotherapi
upregul
heparanas
known
promot
myeloma
growth
suggest
therapeut
target
heparanas
anticanc
therapi
may
improv
patient
outcom
hpatg
mice
overexpress
heparanas
far
sensit
control
mice
dmbatpa
skin
carcinogenesi
exhibit
tenfold
increas
number
size
tumor
lesion
convers
dmbatpainduc
tumor
format
greatli
attenu
hpako
mice
lack
heparanas
point
critic
role
heparanas
skin
tumorigenesi
support
observ
heparanas
inhibitor
potent
suppress
tumor
progress
model
system
find
establish
heparanas
exert
protumorigen
properti
earli
stage
tumor
initi
cooper
ra
dramat
promot
malign
develop
studi
emphas
cooper
heparanas
master
oncogen
ra
provid
evid
heparanas
express
human
follicular
diffus
nonhodgkin
blymphoma
heparanas
inhibitor
restrain
growth
tumor
xenograft
produc
lymphoma
cell
line
furthermor
describ
develop
character
heparanaseneutr
monoclon
antibodi
inhibit
cell
invas
tumor
metastasi
hallmark
heparanas
activ
use
luciferaselabel
raji
lymphoma
cell
show
heparanaseneutr
monoclon
antibodi
profoundli
inhibit
tumor
load
mous
bone
associ
reduc
cell
prolifer
angiogenesi
notabl
found
raji
cell
lack
intrins
heparanas
activ
tumor
xenograft
produc
cell
line
exhibit
typic
heparanas
activ
like
contribut
host
cell
compos
tumor
microenviron
antiheparanas
neutral
monoclon
antibodi
attenu
lymphoma
growth
target
heparanas
tumor
microenviron
research
focus
import
heparanas
sustain
immuneepitheli
crosstalk
underli
colitisassoci
tumorigenesi
use
histolog
specimen
ulcer
coliti
uc
patient
mous
model
dextran
sodium
sulfateinduc
coliti
found
heparanas
constantli
overexpress
activ
throughout
diseas
demonstr
use
heparanaseoverexpress
transgen
mice
heparanas
overexpress
markedli
increas
incid
sever
colitisassoci
colon
tumor
found
highli
coordin
interact
epitheli
compart
contribut
heparanas
mucos
macrophag
preserv
chronic
inflammatori
condit
creat
tumorpromot
microenviron
character
enhanc
signal
induct
result
indic
heparanas
gener
viciou
cycl
power
coliti
associ
tumorigenesi
heparanas
act
synergist
intestin
flora
stimul
macrophag
activ
macrophag
induc
product
via
mechan
activ
via
secret
cathepsin
l
heparanas
contribut
colon
epithelium
thu
disrupt
heparanasedriven
chronic
inflammatori
circuit
highli
relev
design
therapeut
intervent
coliti
associ
cancer
studi
focus
role
heparanas
regul
express
releas
cytokin
human
murin
immun
cell
ex
vivo
treatment
human
peripher
blood
mononuclear
cell
heparanas
result
releas
rang
proinflammatori
cytokin
includ
tnf
similar
pattern
cytokin
releas
also
observ
cell
treat
solubl
hs
furthermor
heparanaseinduc
cytokin
releas
abolish
enzymaticinhibitor
heparanas
suggest
process
mediat
via
enzymat
releas
cell
surfac
hs
fragment
solubl
hs
signal
tolllik
receptor
tlr
pathway
heparanas
may
promot
upregul
cytokin
gener
heparanasecleav
fragment
hs
support
hypothesi
mous
spleen
cell
lack
key
tlr
adaptor
molecul
demonstr
abolit
cytokin
releas
heparanas
stimul
furthermor
spleen
cell
show
reduc
cytokin
releas
respons
heparanas
treatment
suggest
involv
respons
consist
observ
pathway
involv
cytokin
upregul
identifi
data
identifi
new
mechan
heparanas
promot
releas
proinflammatori
cytokin
like
import
regul
cell
migrat
inflamm
heparanas
trigger
upregul
proinflammatori
cytokin
gener
heparanasecleav
fragment
hs
appli
genet
approach
examin
behavior
function
macrophag
isol
wildtyp
wt
heparanaseknockout
hpako
mice
hpako
macrophag
express
lower
level
cytokin
eg
exhibit
lower
motil
phagocyt
capac
intriguingli
inocul
control
monocyt
togeth
lewi
lung
carcinoma
llc
cell
hpako
mice
result
nearli
complet
inhibit
tumor
growth
strike
contrast
inocul
llc
cell
togeth
monocyt
isol
hpako
mice
affect
tumor
growth
indic
heparanas
critic
requir
activ
function
macrophag
mechanist
describ
linear
cascad
heparanas
activ
erk
jnk
signal
macrophag
lead
increas
cfo
level
induct
cytokin
express
manner
appar
requir
heparanas
enzymat
activ
heparanas
key
mediat
macrophag
activ
function
tumorigenesi
crosstalk
tumor
microenviron
overexpress
heparanas
associ
increas
tam
infiltr
experiment
human
pdac
moreov
macrophag
deriv
heparanaserich
tumor
grew
faster
mous
host
display
pronounc
procancer
phenotyp
evidenc
overexpress
vegf
increas
product
import
player
pdac
pathogenesi
furthermor
vitro
heparanas
enzymerend
macrophag
stimul
necrot
cell
often
present
pdac
tissu
procancer
exemplifi
enhanc
product
key
cytokin
implic
pdac
includ
well
abil
induc
signal
augment
pancreat
carcinoma
cell
prolifer
agreement
observ
activ
experiment
clinic
specimen
heparanaseoverexpress
pdac
find
underscor
novel
function
heparanas
molecular
decisionmak
guid
cancerpromot
action
tam
impli
heparanas
express
statu
may
becom
highli
relev
defin
target
patient
subgroup
like
benefit
treatment
modal
target
heparanas
play
key
role
molecular
decisionmak
guid
cancerpromot
action
tumor
associ
macrophag
heparan
sulfat
mimet
antilymphoma
effect
requir
nk
cell
activ
hs
mimet
develop
antitumor
agent
design
suppress
angiogenesi
metastasi
inhibit
heparanas
compet
hsbind
domain
angiogen
growth
factor
howev
exert
antitumor
effect
remain
incomplet
defin
use
murin
model
lymphoma
determin
antitumor
effect
critic
depend
nk
cell
activ
nk
cell
activ
requir
demonstr
activ
directli
instead
enhanc
activ
elev
ligand
cpg
dc
specif
treatment
result
cpg
accumul
lysosom
compart
dc
lead
enhanc
product
essenti
nk
cell
activ
overal
result
reveal
activ
nk
cell
activ
critic
antitumor
effect
moreov
find
may
import
implic
improv
nk
cellbas
antitumor
therapi
heparanas
augment
inflammatori
chemokin
product
colorect
carcinoma
cell
line
explor
possibl
role
heparanas
tumorhost
crosstalk
examin
whether
heparanas
influenc
express
inflammatori
chemokin
colorect
cancer
cell
murin
colorect
carcinoma
cell
incub
heparanas
upregul
kc
rant
gene
releas
kc
protein
heparanasedepend
product
detect
two
human
colorect
carcinoma
cell
line
addit
heparanas
inhibitor
heparastatin
influenc
product
latent
matur
form
heparanas
augment
releas
suggest
heparanas
catalyt
activ
dispens
product
contrast
addit
heparin
medium
suppress
releas
dosedepend
manner
similarli
target
suppress
rnai
significantli
suppress
cell
surfac
express
hs
product
colon
cell
taken
togeth
conclud
colon
cell
transduc
heparanasemedi
signal
hs
bind
propos
novel
function
heparanas
independ
endoglycosidas
activ
name
stimul
chemokin
product
surveil
nk
cell
highli
effici
prevent
cancer
metastasi
infrequ
found
core
primari
tumor
demonstr
freshli
isol
mous
human
nk
cell
express
low
level
heparanas
increas
upon
nk
cell
activ
heparanas
defici
affect
develop
differenti
tissu
local
nk
cell
steadyst
condit
howev
mice
lack
heparanas
specif
nk
cell
hpseflfl
mice
highli
tumor
prone
challeng
carcinogen
methylcholanthren
mca
hpseflfl
mice
also
suscept
tumor
growth
litterm
control
challeng
establish
mous
lymphoma
cell
line
overexpress
nk
cell
group
ligand
inocul
metastat
melanoma
prostat
carcinoma
mammari
carcinoma
cell
line
nk
cell
invas
primari
tumor
recruit
site
metastasi
strictli
depend
presenc
heparanas
cytokin
immun
checkpoint
blockad
immunotherapi
metastas
compromis
nk
cell
lack
heparanas
data
suggest
heparanas
play
critic
role
nk
cell
invas
tumor
therebi
tumor
progress
metastas
consid
system
treat
cancer
patient
heparanas
inhibitor
sinc
potenti
advers
effect
nk
cell
infiltr
might
limit
antitumor
activ
inhibitor
adopt
transfer
chimer
antigen
receptor
car
redirect
lymphocyt
cart
cell
less
strike
therapeut
effect
solid
tumor
lymphoid
malign
although
activ
tumormedi
immunosuppress
may
role
limit
efficaci
cart
cell
function
chang
lymphocyt
ex
vivo
manipul
may
also
account
reduc
abil
cultur
cart
cell
penetr
stromarich
solid
tumor
compar
lymphoid
tissu
therefor
studi
capac
human
vitrocultur
cart
cell
degrad
compon
ecm
contrast
freshli
isol
lymphocyt
found
vitrocultur
lymphocyt
lack
express
enzym
heparanas
hpse
degrad
heparan
sulfat
proteoglycan
main
compon
ecm
found
hpse
mrna
downregul
vitroexpand
cell
may
consequ
offici
known
encod
tumor
protein
bind
hpse
gene
promot
therefor
engin
cart
cell
express
hpse
show
improv
capac
degrad
ecm
promot
tumor
cell
infiltr
antitumor
activ
use
strategi
may
enhanc
activ
cart
cell
individu
stromarich
solid
tumor
see
chapter
volum
inform
heparanas
inflamm
cell
immun
system
increas
express
secret
heparanas
hpa
tumor
cell
promot
tumor
invas
tissu
destruct
angiogenesi
metastasi
show
exist
breast
cancer
patient
hpaspecif
lymphocyt
fluorescenceactiv
cell
sort
flow
cytometri
use
hpa
peptidemhc
class
tetram
furthermor
show
memori
tcell
respons
high
proport
breast
cancer
patient
hpaderiv
peptid
lead
product
ifngamma
gener
antitumor
ctl
lyse
breast
cancer
cell
ctl
recogn
endogen
process
respect
hpa
peptid
hpatransfect
hpaexpress
untransfect
breast
carcinoma
cell
accord
result
fact
cell
found
healthi
peopl
hpa
seem
attract
new
tumorassoci
antigen
peptid
ought
good
candid
peptid
vaccin
reactiv
memori
immun
respons
invas
metastat
cancer
cell
heparanas
broadli
express
variou
advanc
tumor
serv
univers
tumorassoci
antigen
although
sever
epitop
heparanas
antigen
known
human
correspond
knowledg
mice
still
rather
limit
present
studi
design
predict
identifi
ctl
epitop
mous
heparanas
protein
result
show
test
peptid
effector
induc
peptid
mous
heparanas
residu
posit
lsllfkkl
fsygffvi
lyse
three
kind
carcinoma
cell
express
heparanas
k
b
melanoma
cell
lymphoma
cell
lewi
lung
cancer
cell
vivo
experi
indic
peptid
offer
possibl
immun
tumor
also
treat
tumorbear
host
success
result
suggest
peptid
novel
k
b
restrict
ctl
epitop
capabl
induc
heparanasespecif
ctl
vitro
vivo
epitop
may
serv
valuabl
tool
preclin
evalu
vaccin
strategi
heparan
sulfat
heparanas
play
key
role
mous
cell
surviv
autoimmun
diabet
autoimmun
type
diabet
aris
spontan
nod
mice
consid
model
human
character
invas
pancreat
islet
mononuclear
cell
mnc
ultim
lead
destruct
insulinproduc
cell
although
cell
depend
molecular
mechan
trigger
cell
death
fulli
elucid
report
hs
express
extraordinarili
high
level
within
mous
islet
essenti
cell
surviv
vitro
cell
rapidli
lost
hs
die
cell
death
prevent
hs
replac
treatment
also
render
cell
resist
damag
ro
vivo
autoimmun
destruct
islet
nod
mice
associ
product
catalyt
activ
heparanas
isletinfiltr
mnc
loss
islet
hs
furthermor
vivo
treatment
heparanas
inhibitor
preserv
intraislet
hs
protect
nod
mice
result
identifi
hs
critic
molecular
requir
islet
cell
surviv
hs
degrad
mechan
cell
destruct
henc
preserv
islet
hs
could
therapeut
strategi
prevent
see
chapter
simeonov
et
al
inform
heparanas
immun
diabet
mice
diabet
nephropathi
dn
major
lifethreaten
complic
diabet
abnorm
permselect
glomerular
basement
membran
gbm
play
import
role
dn
pathogenesi
loss
gbm
hs
diabet
kidney
associ
increas
glomerular
express
heparanas
point
essenti
involv
heparanas
dn
use
hpseko
mice
found
delet
heparanas
gene
protect
diabet
mice
dn
furthermor
investig
molecular
mechan
underli
induct
enzym
dn
found
transcript
factor
earli
growth
respons
respons
activ
heparanas
promot
diabet
condit
specif
heparanas
inhibitor
markedli
decreas
extent
albuminuria
renal
damag
mous
model
dn
collect
result
underscor
crucial
role
heparanas
pathogenesi
dn
potenti
highli
relev
target
therapeut
intervent
patient
dn
diabet
nephropathi
dn
lead
caus
ckd
western
world
endothelin
receptor
antagonist
emerg
novel
treatment
dn
mechan
underli
protect
effect
remain
unknown
previous
show
heparanas
essenti
develop
dn
investig
role
protein
dn
demonstr
activ
podocyt
releas
heparanas
furthermor
condit
podocyt
cultur
medium
increas
glomerular
transendotheli
albumin
passag
heparanasedepend
manner
mice
podocytespecif
knockout
endothelin
receptor
prevent
diabetesinduc
increas
glomerular
heparanas
express
consequ
reduct
heparan
sulfat
express
endotheli
glycocalyx
thick
develop
proteinuria
observ
wildtyp
counterpart
data
suggest
diabet
signal
occur
endotheli
activ
induc
heparanas
express
podocyt
damag
glycocalyx
proteinuria
renal
failur
thu
prevent
effect
may
constitut
mechan
action
endothelin
receptor
blocker
dn
studi
underscor
crucial
role
heparanas
pathogenesi
diabet
nephropathi
see
chapter
massola
et
al
abassi
goligorski
inform
heparanas
fibrosi
kidney
dysfunct
diabet
heart
singular
relianc
fatti
acid
fa
energi
product
achiev
increas
coronari
lipoprotein
lipas
lpl
break
circul
triglycerid
coronari
lpl
origin
cardiomyocyt
transloc
vascular
lumen
enzym
requir
liber
myocyt
surfac
hs
activ
need
sustain
chronic
hyperglycemia
investig
mechan
endotheli
cell
ec
cardiomyocyt
oper
togeth
enabl
continu
transloc
lpl
diabet
ec
cocultur
myocyt
expos
high
glucos
uptak
endotheli
heparanas
myocyt
determin
upon
uptak
effect
nuclear
entri
heparanas
also
investig
streptozotocin
model
diabet
use
expand
vitro
observ
high
glucos
ecderiv
latent
heparanas
taken
cardiomyocyt
caveolaedepend
pathway
use
hspg
latent
heparanas
convert
activ
form
myocyt
lysosom
enter
nucleu
upregul
gene
express
matrix
net
effect
increas
shed
hspg
myocyt
surfac
releas
lpl
onward
transloc
coronari
lumen
ecderiv
heparanas
regul
abil
cardiomyocyt
send
lpl
coronari
lumen
adapt
although
acut
benefici
could
catastroph
chronic
excess
fa
caus
lipotox
inhibit
heparanas
function
could
offer
new
strategi
manag
cardiomyopathi
observ
diabet
see
also
comment
entitl
heparanas
shake
hand
lipoprotein
lipas
tale
two
cell
see
chapter
chang
et
al
inform
heparanas
cardiomyocyt
amyloid
diseas
encompass
medic
disord
includ
amyloid
protein
aa
amyloidosi
alzheim
diseas
type
diabet
common
featur
condit
select
organ
deposit
diseasespecif
fibrillar
protein
along
sulfat
glycosaminoglycan
hs
test
suscept
hpatg
mice
amyloid
induct
drastic
shorten
hs
chain
observ
heparanaseoverproduc
organ
liver
kidney
site
select
escap
amyloid
deposit
experiment
induct
inflammationassoci
aa
amyloidosi
wherea
tissu
control
anim
heavili
infiltr
amyloid
contrast
spleen
transgen
mice
fail
significantli
overexpress
heparanas
remain
suscept
amyloid
deposit
find
provid
direct
vivo
evid
heparan
sulfat
essenti
develop
amyloid
diseas
see
chapter
li
zhang
inform
heparanas
amyloidosi
heparanas
regul
thrombosi
vascular
injuri
stentinduc
flow
disturb
purpos
studi
examin
role
heparanas
control
thrombosi
follow
vascular
injuri
endovascular
stent
absenc
vascular
injuri
wild
type
heparanas
overexpress
hpatg
mice
similar
time
thrombosi
laserinduc
arteri
thrombosi
model
howev
presenc
vascular
injuri
time
thrombosi
dramat
reduc
hpatg
mice
ex
vivo
system
use
flow
blood
wild
type
hpatg
mice
stent
stent
arteri
segment
anim
type
studi
demonstr
markedli
increas
thrombos
stent
blood
isol
hpatg
mice
comparison
blood
wild
type
anim
found
blood
hpatg
anim
markedli
increas
thrombosi
appli
stent
arteri
segment
either
wild
type
hpatg
mice
result
indic
heparanas
power
mediat
thrombosi
context
vascular
injuri
stentinduc
flow
disturb
lung
injuri
experiment
sepsi
sepsi
system
inflammatori
respons
infect
commonli
progress
acut
lung
injuri
ali
inflammatori
lung
diseas
high
morbid
postul
sepsisassoci
ali
initi
degrad
pulmonari
endotheli
glycocalyx
lead
neutrophil
adher
inflamm
use
intravit
microscopi
found
endotoxemia
mice
rapidli
induc
pulmonari
microvascular
glycocalyx
degrad
via
tumor
necrosi
depend
mechan
glycocalyx
degrad
involv
specif
loss
heparan
sulfat
coincid
activ
endotheli
heparanas
heparan
sulfatespecif
glucuronidas
glycocalyx
degrad
increas
avail
endotheli
surfac
adhes
molecul
circul
microspher
contribut
neutrophil
adhes
heparanas
inhibit
prevent
endotoxemiaassoci
glycocalyx
loss
neutrophil
adhes
accordingli
attenu
sepsisinduc
ali
mortal
mice
find
potenti
relev
human
diseas
sepsisassoci
respiratori
failur
human
associ
higher
plasma
heparan
sulfat
degrad
activ
moreov
heparanas
content
higher
human
lung
biopsi
show
diffus
alveolar
damag
normal
human
lung
tissu
see
addit
studi
heparanas
glycocalyx
heparanas
heparanas
exert
strong
protumorigen
properti
promot
aspect
tumor
develop
tumor
initi
growth
metastasi
chemoresist
enzym
express
tumor
cell
cell
tumor
microenviron
function
extracellularli
well
insid
cell
collect
emerg
premis
heparanas
express
tumor
cell
cell
tumor
microenviron
domin
regul
aggress
phenotyp
cancer
import
contributor
poor
outcom
cancer
patient
prime
target
therapi
investig
heparanas
proce
new
role
enzym
divers
process
signal
transduct
gene
regul
exosom
format
autophagi
activ
innat
immun
cell
chemoresist
emerg
thu
widen
impact
enzym
appear
heparanas
function
extracellularli
remodel
ecm
regul
bioavail
ecmbound
factor
well
insid
cell
augment
among
effect
gene
transcript
hs
turnov
unravel
aspect
heparanas
biolog
ongo
critic
understand
multipl
function
health
diseas
central
downstream
effect
heparanas
enzym
abil
regul
gene
transcript
molecular
level
nuclear
heparanas
appear
among
effect
regul
histon
lysin
methyl
influenc
recruit
demethylas
transcript
activ
gene
yet
understand
heparanas
nuclear
access
mode
action
far
complet
import
challeng
field
rest
structurebas
ration
develop
clinic
effect
inhibitor
heparin
mimic
neutral
antibodi
small
molecul
heparanas
appli
treat
cancer
inflamm
diseas
limit
factor
antiheparanas
drug
develop
lack
high
throughput
screen
valid
assay
assay
continu
use
heterogen
substrat
prepar
derivat
hs
heparinlmwh
variou
way
assay
limit
heterogen
semiquantit
natur
multipl
enzym
cleavag
site
inappropri
use
biolog
sampl
advanc
synthesi
simpl
synthet
oligosaccharid
substrat
singl
point
cleavag
ultim
lead
gold
standard
assay
detail
kinet
analys
also
undesir
effect
antiheparanas
therapi
consid
exampl
recent
report
heparanas
play
critic
role
nk
cell
invas
tumor
therebi
tumor
progress
metastas
shown
cytokin
immun
checkpoint
blockad
immunotherapi
metastas
compromis
nk
cell
lack
heparanas
likewis
found
contrast
freshli
isol
lymphocyt
hpse
mrna
downregul
vitroexpand
cell
may
explain
reduc
abil
cultur
cart
cell
penetr
stromarich
solid
tumor
compar
lymphoid
tissu
fact
engin
cart
cell
express
hpse
result
improv
capac
degrad
ecm
promot
tumor
cell
infiltr
antitumor
activ
suggest
use
strategi
might
enhanc
activ
cart
cell
individu
stromarich
solid
tumor
result
consid
system
treat
cancer
patient
heparanas
inhibitor
sinc
potenti
advers
effect
nk
cart
cell
cell
infiltr
might
limit
antitumor
activ
inhibitor
yet
effect
appear
neglig
given
heparanas
knockout
mice
exhibit
obviou
immunolog
deficit
impli
inhibit
heparanas
caus
minim
side
effect
cancer
patient
remark
heparanas
inhibitor
effect
even
xenograft
tumor
cell
devoid
heparanas
emphas
signific
heparanas
contribut
cell
resid
tumor
microenviron
appear
target
tumor
microenviron
heparanas
inhibitor
enhanc
antitumor
activ
approv
therapi
provid
strong
rational
appli
antiheparanas
therapi
combin
convent
anticanc
drug
anoth
topic
interest
crosstalk
heparanas
heparanas
close
homolog
heparanas
devoid
heparanas
enzymat
activ
unlik
heparanas
role
play
normal
physiolog
patholog
disord
still
larg
obscur
appear
attenu
tumor
growth
via
inhibit
heparanas
decreas
express
proangiogen
mediat
induc
manifest
gene
involv
tumor
suppress
cell
differenti
see
chapter
mckenzi
robert
woolf
book
appear
function
heparanas
activityand
hsdepend
independ
manner
regul
express
select
gene
affect
tumor
vascular
tumor
fibrosi
cell
differenti
apoptosi
cancer
cell
result
tumor
suppress
clearli
research
need
order
appreci
scope
function
crosstalk
heparanas
person
note
would
like
close
person
note
becam
interest
cell
interact
ecm
year
ago
finish
postdoctor
research
supervis
prof
deni
gospodarowicz
ucsf
among
first
realiz
ecm
play
activ
role
orchestr
cellular
respons
normal
patholog
situat
emerg
concept
one
activ
interplay
cell
ecm
cell
synthes
matrix
compon
turn
dictat
regul
cell
shape
function
impact
studi
clearli
indic
current
awar
ecm
tumor
microenviron
key
element
regul
cell
surviv
cancer
progress
year
return
israel
becam
interest
degrad
ecm
hs
mean
understand
better
tumor
cell
enter
exit
blood
vessel
process
cancer
metastasi
decid
focu
hs
know
polyanion
polysaccharid
bind
constitu
ecm
play
import
role
assembl
stabil
entir
supramolecular
structur
ecm
becam
interest
heparanas
enzym
topic
kept
busi
sinc
first
paper
heparanas
cancer
metastasi
publish
parallel
studi
report
dr
nicolson
et
al
next
report
sequenti
mode
heparanas
action
degrad
ecm
inhibit
speci
heparin
express
platelet
neutrophil
activ
cell
immun
system
import
concept
brought
studi
perform
sabbat
michael
klagsbrun
late
judah
folkman
harvard
medic
center
reveal
hs
ecm
provid
storag
depot
henc
heparanas
regul
bioavail
concept
ecm
reservoir
bioactiv
molecul
becam
well
recogn
prime
import
current
appreci
tumor
microenviron
signific
cancer
progress
treatment
studi
emphas
need
purifi
heparanas
protein
clone
respect
gene
object
took
long
time
final
achiev
publish
back
back
studi
perform
group
cristoph
parish
canberra
gene
clone
enabl
studi
mode
heparanas
gene
regul
cellular
uptak
lysosom
storag
activ
other
reveal
mode
heparanas
action
elicit
angiogenesi
tumorigenesi
signal
transduct
thu
year
follow
clone
function
repertoir
heparanas
complex
system
still
reveal
activ
mainli
implic
cell
invas
associ
tumor
metastasi
heparanas
turn
multifacet
protein
appear
particip
essenti
major
aspect
tumor
progress
pathogenesi
diseas
importantli
crystal
structur
heparanas
protein
resolv
pave
way
ration
design
optim
sitedirect
heparanaseinhibit
small
molecul
monoclon
antibodi
direct
result
subsequ
studi
perform
group
us
heparanas
advanc
obscur
enzym
poorli
understood
function
highli
promis
novel
drug
target
offer
new
treatment
strategi
variou
cancer
diseas
ie
chronic
inflamm
diabet
nephropathi
signific
heparanas
valid
target
anticanc
drug
develop
reinforc
studi
indic
mark
inhibit
human
myeloma
lymphoma
glioma
sarcoma
mesothelioma
pancreat
tumor
growth
mice
treat
heparinlik
heparanaseinhibit
compound
ie
roneparstat
pixatimod
examin
clinic
trial
alon
combin
drug
unfortun
yet
rais
questiondilemma
wise
focu
invest
much
time
energi
effort
studi
singl
molecul
realli
understand
mode
heparanas
action
tumorigenesi
adopt
anoth
way
think
focu
diseas
object
unbias
interpret
result
mistak
done
along
way
final
goal
basic
scientist
translat
find
drug
worth
etc
see
also
ilan
et
al
chap
volum
obvious
simpl
clear
cut
answer
focus
one
molecul
riski
nowaday
era
big
scienc
regard
old
fashion
approach
yet
heparanas
journey
activ
ongo
evalu
broad
context
cell
interact
ecm
tumor
microenviron
fact
heparanas
research
markedli
reinforc
signific
ecm
control
cell
prolifer
differenti
led
import
often
unexpect
observ
divers
normal
patholog
process
includ
wound
heal
angiogenesi
autophagi
signal
transduct
protein
traffick
lysosom
secret
blood
coagul
epithelialmesenchym
transit
activ
immun
cell
exosom
format
drug
resist
gene
transcript
other
studi
emphas
involv
heparanas
cancer
progress
patholog
investig
among
diabet
diabet
complic
ie
diabet
nephropathi
diabet
cardiomyopathi
kidney
dysfunct
fibrosi
inflammatori
disord
ie
neuroinflamm
pancreat
ulcer
coliti
arthriti
sepsi
amyloidosi
atherosclerosi
other
interestingli
heparanas
accomplish
exert
enzymat
nonenzymat
function
mostli
hsdepend
yet
case
hsindepend
comparison
ecm
degrad
enzym
ie
mmp
cathepsin
heparanas
field
small
leav
enough
room
research
group
join
make
signific
contribut
basic
translat
aspect
exampl
littl
known
put
nonh
heparanas
receptor
bind
enzym
mediat
downstream
signal
function
likewis
indepth
research
need
elucid
better
mode
heparanas
nuclear
transloc
transcript
activ
well
abil
activ
macrophag
mediat
polar
open
area
refer
review
heparanas
homolog
devoid
heparanas
enzymat
activ
particular
interest
resolv
crystal
structur
elucid
mode
action
tumor
suppressor
reveal
signific
crosstalk
heparanas
prime
import
translat
point
view
appli
crystal
structur
heparanas
ration
design
heparanaseinhibit
small
molecul
neutral
monoclon
antibodi
hsmimick
compound
endow
good
pharmacokinet
examin
effici
anim
model
cancer
patient
